HC Wainwright Issues Optimistic Estimate for AxoGen Earnings

AxoGen, Inc. (NASDAQ:AXGN) – Analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for AxoGen in a research report issued on Thursday, October 29th. HC Wainwright analyst Y. Chen now anticipates that the medical equipment provider will post earnings of ($0.34) per share for the year, up from their previous estimate of ($0.46). HC Wainwright currently has a “Buy” rating and a $56.00 target price on the stock. The consensus estimate for AxoGen’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for AxoGen’s Q4 2026 earnings at ($0.01) EPS, Q1 2027 earnings at ($0.04) EPS, Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.04 EPS, Q4 2027 earnings at $0.09 EPS and FY2027 earnings at $0.10 EPS.

AxoGen (NASDAQ:AXGN) last released its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.08. The company had revenue of $75.83 million during the quarter, compared to analyst estimates of $73.45 million. AxoGen had a negative return on equity of 7.18% and a negative net margin of 11.96%.

Several other analysts also recently weighed in on the company. Wall Street Zen upgraded AxoGen from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Citizens Jmp raised their target price on shares of AxoGen from $50.00 to $55.00 and gave the stock a “market outperform” rating in a report on Thursday, July 30th. Morgan Stanley downgraded shares of AxoGen to a “hold” rating in a research note on Tuesday, September 29th. Bank of America assumed coverage on shares of AxoGen in a research note on Monday, October 12th. They issued a “buy” rating and a $52.00 target price on the stock. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $60.00 price target on shares of AxoGen in a report on Wednesday, October 28th. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, AxoGen currently has an average rating of “Moderate Buy” and an average price target of $57.92.

AxoGen Price Performance

AXGN opened at $49.85 on Tuesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.60 and a quick ratio of 5.04. The stock’s 50 day simple moving average is $42.84 and its 200 day simple moving average is $39.54. The firm has a market cap of $2.68 billion, a price-to-earnings ratio of -76.69 and a beta of 1.17. AxoGen has a 1 year low of $21.92 and a 1 year high of $52.91.

Insiders Place Their Bets

In other news, Director Joseph A. Tyndall sold 3,500 shares of AxoGen stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total value of $173,950.00. Following the sale, the director directly owned 10,650 shares in the company, valued at approximately $529,305. This trade represents a 24.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Wendell sold 13,353 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $48.42, for a total value of $646,552.26. Following the transaction, the director directly owned 107,976 shares in the company, valued at $5,228,197.92. This trade represents a 11.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 98,503 shares of company stock worth $4,656,947. 2.44% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in shares of AxoGen during the 2nd quarter valued at about $204,123,000. Artemis Investment Management LLP increased its position in shares of AxoGen by 27.5% during the third quarter. Artemis Investment Management LLP now owns 1,780,992 shares of the medical equipment provider’s stock valued at $74,659,000 after buying an additional 384,200 shares during the period. Wellington Management Group LLP increased its position in shares of AxoGen by 44.3% during the second quarter. Wellington Management Group LLP now owns 1,391,654 shares of the medical equipment provider’s stock valued at $64,280,000 after buying an additional 427,089 shares during the period. Bamco Inc. NY purchased a new position in shares of AxoGen during the second quarter valued at about $34,190,000. Finally, TimesSquare Capital Management LLC bought a new position in AxoGen in the second quarter worth about $31,863,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

About AxoGen

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.